Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reverse-phase protein microarrays for tissue-based analysis.

Runa Speer1, Julia D Wulfkuhle, Lance A Liotta

  • 1National Institutes of Health, National Cancer Institute, Center for Cancer Research, FDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Bethesda, MD 20892, USA.

Current Opinion in Molecular Therapeutics
|June 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.

Cell death & disease·2026
Same author

Laser capture microdissection.

Nature reviews. Methods primers·2026
Same author

Immunoproteomic insights into inflammatory diseases of the critically endangered black rhinoceros (Diceros bicornis).

Scientific reports·2026
Same author

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

NPJ precision oncology·2026
Same author

Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.

NPJ precision oncology·2026
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Genomics alone is insufficient for understanding disease. Proteomics and systems biology offer a deeper view of cellular processes and protein interactions, crucial for mapping disease pathways.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Systems Biology

Background:

  • Human genome sequencing provides foundational biological insights but is insufficient for understanding complex diseases.
  • Disease pathogenesis necessitates a shift from genomics to proteomics and systems biology for a comprehensive view.
  • Understanding protein function requires analyzing their status and interactions within cellular environments.

Purpose of the Study:

  • To highlight the importance of proteomics in understanding disease mechanisms.
  • To profile the functional state of signaling pathways in normal and diseased states.
  • To develop 'circuit maps' of protein networks for identifying aberrant signaling.

Main Methods:

  • Proteomics analysis goes beyond protein enumeration to characterize functional status and interactions.

Related Experiment Videos

  • Systems biology approaches are essential for mapping complex protein networks.
  • Reverse-phase protein microarrays enable multiplexed profiling of phosphorylated signaling events.

    • Main Results:

    • Proteomics allows for the characterization of proteins in their physiological context.
    • Identifying dysregulated signaling pathways is key to understanding disease.
    • Reverse-phase protein microarrays can profile signaling pathway states even in denatured cell lysates.

    Conclusions:

    • Proteomics and systems biology are crucial for advancing disease understanding beyond genomics.
    • Profiling signaling pathways with technologies like protein microarrays is vital for identifying disease mechanisms.
    • Mapping protein networks aids in the development of targeted therapeutic strategies.